Genetic landscape of FLT3-mutated acute myeloid leukemia (AML) patients treated within the ratify trial (Alliance C10603)
      Google Scholar   
Citation:
HemaSphere vol 3 (suppl 1) 436
Meeting Instance:
EHA 2019
Year:
2019
Type:
Abstract
Sub type:
Poster Discussion
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Parents:
None
Children:
3696   3842  
Program:
TRP
Primary Committee:
Leuk Corr Sci
Sec. Committees:
   
Pharmas:
Novartis  
Grants:
U10CA180821, U10CA180861, U10CA180882, U24CA196171, U10CA180820 (ECOG-ACRIN), U10CA180863 (CCTG), U10CA180888 (SWOG)  
Corr. Author:
 
Authors:
                                                       
Networks:
LAPS-IL036, LAPS-IL057, LAPS-MA036   
Study
CALGB-10603
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: